BioNTech SE
BioNTech is a global immunotherapy company that researches, develops and commercializes medicines for cancer, infectious diseases and other serious diseases. Its integrated operations include immunology research, drug discovery, clinical development, GMP manufacturing, commercial capabilities, computational medicine, data science, AI and machine learning. Its technology platforms include investigational mRNA immunotherapies and protein-based therapeutics, including monoclonal and bispecific antibodies and antibody-drug conjugates. Oncology is its primary focus, alongside vaccines and therapeutics for infectious diseases. BioNTech’s marketed product is Comirnaty, its COVID-19 vaccine, developed and commercialized with Pfizer. Pfizer holds marketing and distribution rights worldwide apart from Greater China, Germany and Türkiye; BioNTech holds those rights in Germany and Türkiye. BioNTech also develops a broad pipeline of oncology and infectious disease candidates, including individualized mRNA cancer immunotherapies and targeted therapies. It is headquartered in Mainz, Germany.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BNTX in the last 30 days.
See all $BNTX insider activity →Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.
BioNTech opened a clinical-scale mRNA manufacturing and R&D facility at La Trobe University in Melbourne. The facility, focused on cancer, heart disease, and other treatments, uses BioNTainer technology for end-to-end manufacturing. It is expected to be ready for GMP manufacturing by mid-2027. According to BioNTech, the facility aims to support local mRNA research and clinical trials.
HC Wainwright & Co. kept its Buy rating on BioNTech but reduced its price target to $110 from $130, citing a 15.4% decrease. This target suggests a 25.7% upside from BioNTech's Nov 6 closing price of $87.51. Recent analyst notes on BioNTech have price targets ranging from $106 to $132.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning BNTX (BioNTech SE). Coverage has skewed bearish: 4 bullish, 4 neutral, and 6 bearish.
Recent BNTX coverage spans financial news, technology and mergers & acquisitions.
Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.
The new facility expands BioNTech's manufacturing capacity and could boost future revenue streams from mRNA therapeutics and vaccines.
Analyst target cut suggests lower upside expectations.
BioNTech appears financially resilient but still loss‑making, suggesting limited near‑term upside.
Mixed earnings may keep the stock flat or cause modest downside.
AlphAI scores every news story that mentions BNTX with an AI model for sentiment and relevance, and aggregates insider trades from BioNTech SE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Scholar Rock (SRRK) agreed to sell its FDA Priority Review Voucher to BioNTech for $205M in cash. The payment is due at closing, pending regulatory approval. The voucher was awarded after FDA approval of ISEMBYLD. The transaction aims to monetize the voucher.
BioNTech opened a clinical-scale mRNA manufacturing and R&D facility at La Trobe University in Melbourne. The facility, focused on cancer, heart disease, and other treatments, uses BioNTainer technology for end-to-end manufacturing. It is expected to be ready for GMP manufacturing by mid-2027. According to BioNTech, the facility aims to support local mRNA research and clinical trials.
HC Wainwright & Co. kept its Buy rating on BioNTech but reduced its price target to $110 from $130, citing a 15.4% decrease. This target suggests a 25.7% upside from BioNTech's Nov 6 closing price of $87.51. Recent analyst notes on BioNTech have price targets ranging from $106 to $132.
BioNTech (BNTX) and Moderna (MRNA) face declining COVID-19 vaccine revenue, focusing on mRNA-based cancer treatments. BioNTech reported $3.2B revenue in FY 2025, a 4.3% increase, but a $1.3B net loss. Moderna saw a 40% revenue decline to $1.9B in FY 2025 but reported a Q3 2026 profit of $162M. Both have substantial cash reserves, with BioNTech holding €16.2B and Moderna $8B. BioNTech is preferred for its financial resilience and oncology pipeline.
Axsome Therapeutics (AXSM) and BioNTech (BNTX) are compared for long-term investment potential. AXSM focuses on CNS disorders, reporting $638.5M revenue in FY 2025 but a net loss of $183.2M. BNTX, known for COVID-19 vaccines, had $3.2B revenue and a $1.3B net loss. AXSM has higher debt and lower cash flow, while BNTX has no debt and strong liquidity. AXSM's Auvelity drug is gaining market share, while BNTX faces revenue decline from fading vaccine sales.
Analysts from Jefferies and Canaccord Genuity maintained Buy ratings on BioNTech (BNTX), with price targets of $138 and $132, respectively. Meanwhile, J.P. Morgan and RBC Capital maintained Hold ratings on Sanofi (SNYNF), with targets of EUR95 and EUR75. Both companies have Moderate Buy consensus ratings.
UBS kept its Buy rating on BioNTech but reduced its price target from $135 to $125, a 7.4% cut. This new target suggests a 37.8% upside from the Nov 4 closing price of $90.70. Recent analyst price targets for BioNTech range from $106 to $132.
Morgan Stanley kept BioNTech at Overweight but reduced its price target to $106 from $114, citing a 7% decrease. The new target suggests a 22% upside from the Nov 3 close of $86.92. Recent analyst notes on BioNTech have price targets ranging from $110 to $132.
Wells Fargo kept BioNTech's rating at Overweight but cut its price target to $125 from $140, a 10.7% reduction. This suggests a 43.8% upside from the Nov 3 close of $86.92. Recent analyst targets for BioNTech range from $110 to $132.
BioNTech (BNTX) and Gilead Sciences began a global Phase 3 trial for a new breast cancer treatment combining BioNTech's pumitamig and Gilead's antibody-drug conjugate. The study targets metastatic triple-negative breast cancer, an aggressive subtype with limited treatment options. BioNTech, valued at $22.0 billion, aims to diversify its oncology portfolio as COVID-19 revenue declines.
